Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 12 Dec 2013 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 21 Aug 2013 Planned number of patients changed from 400 to 420 as reported by ClinicalTrials.gov.
- 21 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.